U.S., Nov. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07226726) titled 'Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution' on Nov. 05.
Brief Summary: Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.
Study Start Date: Jan. 01
Study Type: INTERVENTIONAL
Condition:
Congenital Myasthenic Syndrome
Intervention:
BIOLOGICAL: AlloEx exosomes
This is an intranasal treatment of exosomes derived from mesenchymal stem cells.
Recruitment Status: RECRUITING
Sponsor: The Foundation for Orthopaedics and Regenerative Medicine
Disclaimer: Curated by HT Syndication....